In January, Harold Varmus will begin the next stage in an unusual career. He's gone from English literature to medicine to bench science to Washington science bureaucrat, and now he becomes the well-paid (some would say extremely well-paid) president of a private, not-for-profit treatment and research facility, the Memorial Sloan Kettering Cancer Center in New York. He's succeeded in everything else he's tried, so it's a good bet he'll succeed in this latest role, too.
It might seem like the jump from English to medicine was the biggest one, but Varmus will tell you that an even bigger leap was going from scientist to science bureaucrat. By his own admission, just a few years before becoming director of the NIH in 1992 his interest in the politics of science was practically non-existent. He was running a successful lab at the University of California, San Francisco and, with Michael Bishop, he won the 1989 Nobel Prize for Physiology or Medicine for his work on viruses and their relationship to oncogenes.
But as he tells it, in the late 1980s and early 1990s, several events occurred that brought Varmus off the political sidelines. First, a quirk in funding patterns led to an unusually low success rate for new grants, especially among first-time applicants. Second, there was a series of misconduct scandals that seemed to tarnish the public's traditionally high regard for scientists. And finally, the Reagan administration seemed bent on shifting the support for science from basic to applied research as a way of justifying the multi-billion dollar federal research budget.
Varmus felt he couldn't sit idly by in the face of these threats. What's more, his newly bestowed Nobel Prize gave him unusual access to both the media and the political establishment. Varmus entered the fray. In part, he blames two people for getting him engaged: his colleagues Marc Kirschner and Bruce Alberts, both then at UCSF.
Varmus says Alberts in particular convinced him to take a more active role in solving the funding problems facing scientists. And, says Varmus, "when Bruce, as newly elected President of the NAS, was asked to chair a search committee to find a new NIH Director, my fate was sealed." Although outsiders are frequently hauled into Washington, it's rare to put someone at the top of an 11 billion dollar federal agency with no experience of managing anything larger than a personal laboratory.
But those who knew him were convinced Varmus could accomplish anything he set his mind to. "I think Harold not only proved us all right," says UCSF's Keith Yamamoto, "but far exceeded anything any of us expected. He turned out not only to be a capable administrator, even though he lacked that experience, but he has just done a masterful job." Yamamoto says being NIH director did not change Varmus' style all that much. "What Harold did was to go there as a scientist and say, 'look, we can do things the way we do in the laboratory, we can do experiments, and if they work, we can implement them.'' Yamamoto says one of his big achievements was to start to overhaul the peer review process for approving grants. According to Yamamoto the new system will allow for more innovative if more risky research to have a better chance of being funded.
Another project with broad implications is Varmus' plan to put all biomedical research papers online -by means of the new NIH publishing venture, PubMed Central. Tom Pollard, the president of the Salk Institute in La Jolla, says the project reflects the kind of forward thinking Varmus is capable of. "The idea is to allow the scientific community all around the world access to the major publications in an electronic form so that anybody could have access to any piece of information without restriction, whether they were in a small institution here in the US or in any other part of the world." PubMed Central will be launched early next year by the NIH, albeit as a somewhat watered-down version of the original idea.
Although Varmus won widespread praise for his leadership at NIH, both from politicians and fellow science bureaucrats, he never stopped behaving more like a scientist. He maintained an active laboratory within the National Cancer Institute, and rode his bicycle to work, frequently showing up at his office in sweaty clothes, changing into a suit only if the day's activities required.
Varmus is an intense man -not surprising considering all he manages to accomplish in a given day. He can intimidate lesser minds, and has little patience for sloppy thinking. "He's not what I would describe as cuddly," remarks one senior NIH official, "but if he thinks you're right, he'll be one of your fiercest defenders."
Varmus can also be charming and droll. At a recent White House event, Hillary Clinton introduced Varmus as the "outgoing head of NIH," to which Varmus replied, "I assume by 'outgoing' you meant I'm leaving, as opposed to my social behavior."
Varmus plans to continue his scientific research at Memorial Sloan Kettering. He says he wasn't chafing to leave NIH, but when the top job at the New York cancer center came along, he felt he had to jump at it. "I think the next decade or two will be a crucial time for moving our basic understanding of cancer into the clinic in a very powerful way," says Varmus. "To be at an institution that has a strong science base and also a remarkable patient population and a strong history of doing clinical trials and taking good care of patients is an ideal place to be as that revolution occurs." It's a revolution that Varmus has had a large part in fomenting.
Joseph Palca is a correspondent with National Public Radio, and is currently on a Kaiser Family Foundation media fellowship.
Gazetteer The Human Genome Project
What is it famous for? It depends who you talk to but its most ardent supporters think it's the most important biology project ever. Walter Gilbert hailed it as biology's 'Holy Grail'. Francis Collins says it's more important than the moon race, whereas Eric Lander draws comparisons with Mendeleev's periodic Is the project on schedule? It is now, although there have been a few headaches. The French group at Généthon did a great job of building a comprehensive genetic map of the human genome, comprised of thousands of polymorphic markers, but they and others found difficulties in making the corresponding physical map. Improved vectors have now enabled reliable physical maps for all 23 pairs of chromosomes to be constructed.
What's the current state of play? The sequence of the first complete chromosome -chromosome 22 -was published in Nature this month. It contains more than 30 million bases of sequence and includes several hundred genes. Nearly 15% of the human genome sequence is now complete, and another 20% is finished in draft form. Francis Collins, chief of the Human Genome Project, plans to issue a "rough More controversy. In 1998, the infamous Craig Venter formed a new company called Celera Genomics, based in Gaithersburg, Maryland, that aims to sequence the human genome years ahead of the HGP.
What, is Venter nuts? Apparently not. Instead of mapping each chromosome, Celera is using the shotgun sequencing method. The company has about 300 state-of-the-art ABI PRISM 3700 capillary DNA sequencers, which not only are the fastest machines on the market but need almost no human maintenance. They can generate 1 million bases of sequence in 24 hours. The raw sequence data will be assembled using an $80 million mainframe computer specially built for Celera, and will probably take about three months.
What is Celera doing with the data?
The company says it will release the sequence for free, but sell access to its customized database to its pharmaceutical clients. It says it will patent no more than a few hundred human genes, although preliminary applications have already been filed for several thousand genes. Not surprisingly, supporters of the HGP are up in arms about this, arguing that the human genome sequence must be publicly owned.
Who will win the race? Venter claims that by the summer of 2000, Celera will have sequenced 9 billion bases of human DNA, or enough to identify more than 90% of human genes. The company might finish the full sequence in 2001. But many are sceptical of Celera's ability to piece together the full human sequence, and are worried that others will be left the thankless task of filling thousands of gaps in the sequence. At a Congressional hearing in 1998, Maynard Olsen, head of the HGP effort at the University of Washington, challenged Venter to "Show me the data!". Venter plans to do just that, when he publishes the completed genome sequence of Drosophila melanogaster early in 2000.
What will the sequence tell us? The first priority is to determine the identity, if not the actual function, of all human genes. Most textbooks put the number of human genes at 100,000, but another genomics company, Incyte Pharmaceuticals, says there might be more like 140,000. Sequence homologies with the completed genomes of yeast, Drosophila and other organisms will be invaluable. These data will be coupled with information about gene expression, protein structure and metabolic pathways to help reveal physiological function. There is also intense interest in cataloguing sites of sequence variation between individuals. Researchers are assembling thousands of single nucleotide polymorphisms (SNPs) to rapidly screen families and populations for disease genes. Just in the past few months, pharmaceutical companies have touted discoveries of genes underlying psoriasis, diabetes and migraine. This might be the start of the much-vaunted leap in our ability to diagnose, and treat, common human diseases.
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